Cover Image
市場調查報告書

全球乳癌預測遺傳基因檢驗市場預測

Global Breast Cancer Predictive Genetic Testing Market Outlook 2022

出版商 KuicK Research 商品編碼 487386
出版日期 內容資訊 英文 140 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球乳癌預測遺傳基因檢驗市場預測 Global Breast Cancer Predictive Genetic Testing Market Outlook 2022
出版日期: 2017年04月01日 內容資訊: 英文 140 Pages
簡介

本報告提供全球乳癌預測遺傳基因檢驗市場相關調查分析,遺傳性乳癌遺傳基因,乳癌敏銳度的概念,預測癌症篩檢的本質,經濟、道德、社會方面,乳癌的罹患率,預測檢驗的市場、成本分析,乳癌預測檢驗的保險事項相關的系統性資訊。

第1章 癌症敏銳度檢驗

  • 所謂癌症敏銳度
  • 癌症敏銳度檢驗的方面

第2章 乳癌敏銳度

  • 乳癌敏銳度的概念
  • 遺傳的易感基因的痕跡

第3章 遺傳性乳癌遺傳基因

  • 滲透率高的遺傳基因
  • 滲透率中的遺傳基因
  • 滲透率低的遺傳基因

第4章 乳癌敏銳度症候群

  • 遺傳性乳癌、卵巢癌症
  • Cowden氏症候群
  • Li-Fraumeni症候群
  • Peutz-Jeghers症候群

第5章 癌症敏銳度檢驗的本質

  • 癌症敏銳度的必需條件
  • 檢驗的順次階段

第6章 遺傳性癌症敏銳度檢驗

  • 風險評估
  • 遺傳諮詢
  • 遺傳基因檢驗
  • 檢驗後諮詢

第7章 遺傳性風險的管理

  • 監視
  • 化學預防
  • 預防性的兩側性乳房切除

第8章 經濟、倫理的、社會方面

  • 癌症敏銳度檢驗的經濟方面
  • 癌症敏銳度檢驗的道德方面
  • 癌症敏銳度檢驗的社會方面

第9章 全球乳癌罹患率

  • 乳癌發病率
  • 生殖細胞株的乳癌民族性

第10章 各地區的盛行率

  • 先進地區的盛行率
    • 美國
    • 歐洲
    • 加拿大
    • 日本
  • 途中地區的盛行率
    • 中國
    • 印度
    • 非洲

第11章 財政預測

  • 乳癌敏銳度檢驗的成本
  • 乳癌敏銳度檢驗的保險事項

第12章 癌症敏銳度市場方面

  • 乳癌敏銳度市場概要
  • 直銷市場

第13章 全球乳癌預測遺傳基因檢驗市場力學

  • 促進參數
  • 課題

第14章 全球乳癌預測遺傳基因檢驗市場未來發展預測

第15章 競爭情形

  • Cancer Genetics
  • Invitae
  • Iverson Genetics
  • Myriad Genetics
  • NeoGenomics
  • Oncocyte
  • PerkinElmer
  • Quest Diagnostics
  • Roche
  • Thermo Fisher Scientific
目錄

“Global Breast Cancer Predictive Genetic Testing Market Outlook 2022” report analyzes the various aspects related to the emergence and development of breast cancer genetic test market across the globe. The current and future aspects of cancer genomics have covered a long path of advances and the journey is still ongoing. The technological improvements in genomic sciences had allowed parallel sequencing of both tumors and germline mutations and had provided the weapon of next generation sequencing. Under the supervision of intellectual property laws and appropriate guidelines cancer susceptibility testing has become one of the major assets in medical practice. There appears to be pervasive belief in both scientific and public circles that genetic testing is going to be the cornerstone of much, if not all, of what medicine holds for the future. Besides, what is generally meant is the wide scale testing for susceptibility to common diseases especially for cancer and for responsiveness to drugs has come to be described as genetic profiling.

With the knowledge and acceptance of the fact that the breast cancer is on alarming scale, the major concern has been diverted towards this scenario. As there are 5% to 10% of breasts cancer cases which occur due to the germline mutations and the most common ones are the BRCA1 and BRCA2 mutations. Fortunately, these hereditary cancers can be prevented if diagnosed early or even before its occurrence which includes the susceptibility testing of breast cancer genes.

Breast cancer susceptibility has been in existence since 1966 and had served as the boon for the patients as well as the stakeholders. Certainly, 2013 have been the year of major events in the field of predictive genetic testing as US FDA approved the use of next generation DNA sequencing in clinical practice. Further, the decision of Supreme Court invalidated the BRCA patent held by Myriad genetics. These decisions made the new entries and embraced the competitions in the cancer genetics market.

Leading to the current scenario which is completely changing and the market is now subjected to the direct to consumer BRCA testing kits provided by varied pharmaceuticals. However, the new entrants to the global market will face considerable challenges in persuading physicians to choose them as a test provider. New entrants will need to provide indication of subsequent in meeting the requirements of physicians such as reputation, trust, transparency, and counseling. Some of these aspects cannot be established quickly, and take time to establish.

The future holds up for the precision medicine and cancer predictability will be proving a great deal, as through the aid of breast cancer predictive testing and better counseling measures this regimen can turn out into an effective prophylactic modality for hereditary as well as early stage breast cancer. The predictive risk calculations will be leading towards the better management and improved survival rates. Over the next decade or two, it seems likely that the technology will screen entire populations or specific subgroups for genetic information in order to target interventions to individual patients that will improve their health and prevent disease. While the evidence base is still growing, genetic services industry leaders strongly believe that emerging testing capabilities will have significant clinical impact in the future.

“Global Breast Cancer Predictive Genetic Testing Market Outlook 2022” Report Highlights:

  • Hereditary Breast Cancer Genes
  • Conceptual of Breast Cancer Susceptibility
  • Predictive Cancer Testing Essentials
  • Economical, Ethical & Social Aspects
  • Global Prevalence of Breast Cancer
  • Market & Cost Analysis of Predictive Testing
  • Insurance Affairs for Breast Cancer Predictive Testing

Table of Contents

1. Cancer Susceptibility Testing

  • 1.1. Prologue to Cancer Susceptibility
  • 1.2. Aspects of Cancer Susceptibility Testing

2. Breast Cancer Susceptibility

  • 2.1. Conceptual of Breast Cancer Susceptibility
  • 2.2. Trail of the Inherited Susceptible Genes

3. Hereditary Breast Cancer Genes

  • 3.1. High Penetrant Genes
    • 3.1.1. Breast Cancer Gene1(BRCA1)
    • 3.1.2. Breast Cancer Gene 2(BRCA2)
    • 3.1.3. TP53
    • 3.1.4. PTEN
    • 3.1.5. STK11 & CDH1
  • 3.2. Intermediate Penetrant Genes
    • 3.2.1. CHEK2
    • 3.2.2. PALB2
    • 3.2.3. ATM
    • 3.2.4. Other Genes
    • 3.3. Low Penetrant Genes

4. Breast Cancer Susceptible Syndromes

  • 4.1. Hereditary Breast & Ovarian Cancer
  • 4.2. Cowden Syndrome
  • 4.3. Li-Fraumeni Syndrome
  • 4.4. Peutz-Jeghers Syndrome

5. Cancer Susceptibility Testing Essentials

  • 5.1. Prerequisites towards Cancer Susceptibility
  • 5.2. Sequential Stages in Testing

6. Genetic Cancer Susceptibility Testing

  • 6.1. Risk Assessment
  • 6.2. Genetic Counseling
  • 6.3. Genetic Testing
  • 6.4. Post-Test Counseling

7. Management of Hereditary Risk

  • 7.1. Surveillance
  • 7.2. Chemoprevention
  • 7.3. Bilateral Prophylactic Mastectomy

8. Economical, Ethical & Social Aspects

  • 8.1. Economic Aspects of Cancer Susceptibility Testing
  • 8.2. Ethical Aspects of Cancer Susceptibility Testing
  • 8.3. Social Aspects of Cancer Susceptibility Testing

9. Global Prevalence of Breast Cancer

  • 9.1. Breast Cancer Incidences
  • 9.2. Germline Breast Cancer Ethnicity

10. Prevalence over Geographic Regions

  • 10.1. Prevalence in Developed Regions
    • 10.1.1. US
    • 10.1.2. Europe
    • 10.1.3. Canada
    • 10.1.4. Japan
  • 10.2. Prevalence in Developing Regions
    • 10.2.1. China
    • 10.2.2. India
    • 10.2.3. Africa

11. Preface of Monetary Prospects

  • 11.1. Cost of Breast Cancer Susceptibility Testing
  • 11.2. Insurance Affairs for Breast Cancer Susceptibility Testing

12. Aspects of Cancer Susceptibility Market

  • 12.1. Breast Cancer Susceptibility Market Overview
  • 12.2. Direct To Consumer Market

13. Global Breast Cancer Predictive Genetic Testing Market Dynamics

  • 13.1. Accelerative Parameters
  • 13.2. Challenges

14. Global Breast Cancer Predictive Genetic Testing Market Future Aspects

15. Competitive Landscape

  • 15.1. Cancer Genetics
  • 15.2. Invitae
  • 15.3. Iverson Genetics
  • 15.4. Myriad Genetics
  • 15.5. NeoGenomics
  • 15.6. Oncocyte
  • 15.7. PerkinElmer
  • 15.8. Quest Diagnostics
  • 15.9. Roche
  • 15.10. Thermo Fisher Scientific

List of Figures

  • Figure 1-1: Layout of Traditional & Advanced Cancer Susceptibility Testing
  • Figure 2-1: Demonstration of the Potentials Aspects of the Cancer Susceptibility Testing
  • Figure 3-1: Common Genetic Variants of Breast Cancer Susceptible Genes
  • Figure 3-2: Percentage of BRCA1 Gene Mutations & Other Genes for Breast Cancer
  • Figure 3-3: Breast Cancer Risk by Carriers & Non-Carriers with Growing Age
  • Figure 3-4: Representation of Gene Specific Lifetime Breast Cancer Risks
  • Figure 3-5: Percentage of Risk Factors of Breast Cancer & Variability of Penetrance Genes
  • Figure 4-1: Percentage Share of the Causes of Breast Cancer Risk Assessment
  • Figure 4-2: Number of Genes Associated With Hereditary Breast Cancer Syndrome
  • Figure 4-3: The Cumulative Lifetime Risk to Age 70 Years for Breast or Ovarian Cancer
  • Figure 4-4: Li-Fraumani Syndrome Age Related Risk Patterns for Cancer Development
  • Figure 5-1: Advantages of Genetic Cancer Susceptibility Tests
  • Figure 5-2: The Criteria of Target Population for Genetic Testing of Breast Cancer
  • Figure 5-3: Representation of the Sequential Stages in the Cancer Susceptibility Testing
  • Figure 6-1: The Concept of Breast Cancer Risk Assessment & Management
  • Figure 6-2: The Outline of Genetic Test for Breast Cancer Susceptibility
  • Figure 6-3: Interpretation of Possible Outcomes after Cancer Genetic Testing
  • Figure 7-1: Management Strategies of Hereditary Risk of Breast Cancer
  • Figure 7-2: Percentage of Cancer Risk Reductions via Varied Management Strategies
  • Figure 8-1: Proportion of Cost Effectiveness Ratios in Predictive Genetic Test
  • Figure 8-2: Ethical Issues of Breast Cancer Susceptibility Testing
  • Figure 9-1: Global - Demonstration of Incidence & Mortality Rate of Breast Cancer
  • Figure 9-2: Global - Comparative Percentage of Risk of Developing Breast Cancer in Women
  • Figure 9-3: US - Prevalence of BRCA Mutation Percentage among White Population
  • Figure 9-4: UK - Prevalence of BRCA Mutations Percentage among White Population
  • Figure 9-5: Prevalence of Mutations in Ashkenazi Jewish Individuals
  • Figure 10-1: US - Rates of Incidence and Mortality Breast Cancer in US as per 100,000
  • Figure 10-2: US- Prevalence of BRCA1 Mutations Percentage over the Base of Ethnicity
  • Figure 10-3: Europe - Percentage of Incidence & Mortality of Breast Cancer
  • Figure 10-4: UK - Rate of Breast Cancer Incidence Related to Age, 2014
  • Figure 10-5: Europe - Percentage of BRCA1 Mutation in High Risk Families
  • Figure 10-6: Canada - Percentage of All New Cancer Cases & Breast Cancer Cases, 2016
  • Figure 10-7: Canada - Percentage of New Breast Cancer Diagnosed in Canadian Women by Age Group, 2016
  • Figure 10-8: Japan - Incidence Rates of Breast Cancer as per 100,000
  • Figure 10-9: China - Incidence & Mortality Rates in Chinese Population, 2015
  • Figure 10-10: India - Percentage of Increasing Incidence of Breast Cancer in Younger Age Groups
  • Figure 10-11: Central Africa - Age Adjusted Incidence & Death Rates for Breast Cancer
  • Figure 11-1: US - Cost of Breast Cancer Susceptibility Testing (US$)
  • Figure 11-2: UK - Cost of Breast Cancer Susceptibility Testing (US$)
  • Figure 11-3: Canada - Cost Range of Breast Cancer Susceptibility Testing (US$)
  • Figure 11-4: Japan - Cost Range of Breast Cancer Susceptibility Testing (US$)
  • Figure 11-5: Australia & New Zealand - Cost of Breast Cancer Susceptibility Testing (US$)
  • Figure 11-6: China - Cost of Breast Cancer Susceptibility Testing in China (US$)
  • Figure 11-7: India - Cost of Breast Cancer Susceptibility Testing (US$)
  • Figure 11-8: Singapore - Cost of BRCA Testing & Mastectomy
  • Figure 12-1: Myriad's - Market Sales for BRCA Testing (US$ Millions)
  • Figure 12-2: Criticism for the BRCA Testing Genes Patented by Myriad Genetics
  • Figure 12-3: The Cost Comparison of Myriads BRCA Testing & Other Competitors (US$)
  • Figure 12-4: Price Difference between Healthcare BRCA Testing & Direct to Consumer Test
  • Figure 12-5: Global - BRCA Susceptibility Testing Market Opportunity (US$ Million), 2017-2022
  • Figure 12-6: US - BRCA Susceptibility Testing Market Opportunity (US$ Million), 2017-2022
  • Figure 12-7: Europe - BRCA Susceptibility Testing Market Opportunity (US$ Million), 2017-2022
  • Figure 12-8: Asia - BRCA Susceptibility Testing Market Opportunity (US$ Million), 2017-2022
  • Figure 13-1: Global - Major Parameters of Growth in Breast Cancer Susceptibility Testing
  • Figure 13-2: Global - Major Challenges of Breast Cancer Susceptibility Market

List of Tables

  • Table 4-1: High Penetrance Mutation Variants Corresponding to Breast Cancer Syndromes 38
  • Table 7-1: Schedule of Surveillance of Breast Cancer According To Age 63
Back to Top